182 related articles for article (PubMed ID: 28483424)
1. The Effect of Uremic Solutes on the Organic Cation Transporter 2.
Cheung KWK; Hsueh CH; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
J Pharm Sci; 2017 Sep; 106(9):2551-2557. PubMed ID: 28483424
[TBL] [Abstract][Full Text] [Related]
2. The kidney and uremic toxin removal: glomerulus or tubule?
Masereeuw R; Mutsaers HA; Toyohara T; Abe T; Jhawar S; Sweet DH; Lowenstein J
Semin Nephrol; 2014 Mar; 34(2):191-208. PubMed ID: 24780473
[TBL] [Abstract][Full Text] [Related]
3. Disposition and clinical implications of protein-bound uremic toxins.
Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
[TBL] [Abstract][Full Text] [Related]
4. Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3.
Hsueh CH; Yoshida K; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
Mol Pharm; 2016 Sep; 13(9):3130-40. PubMed ID: 27467266
[TBL] [Abstract][Full Text] [Related]
5. Significance of Organic Anion Transporter 2 and Organic Cation Transporter 2 in Creatinine Clearance: Mechanistic Evaluation Using Freshly Prepared Human Primary Renal Proximal Tubule Cells.
Mathialagan S; Chung G; Pye K; Rodrigues AD; Varma MVS; Brown C
J Pharmacol Exp Ther; 2024 Jan; 388(1):201-208. PubMed ID: 37977812
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2.
Arakawa H; Omote S; Tamai I
J Pharm Sci; 2017 Sep; 106(9):2899-2903. PubMed ID: 28336299
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide.
Miyake T; Mizuno T; Mochizuki T; Kimura M; Matsuki S; Irie S; Ieiri I; Maeda K; Kusuhara H
J Pharm Sci; 2017 Sep; 106(9):2542-2550. PubMed ID: 28479364
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Uremic Solute-mediated Inhibition of OAT1/3 Improves PBPK Prediction of Tenofovir Renal and Systemic Disposition in Patients with Severe Kidney Disease.
Chang SY; Huang W; Chapron A; Quiñones AJL; Wang J; Isoherranen N; Shen DD; Kelly EJ; Himmelfarb J; Yeung CK
Pharm Res; 2023 Nov; 40(11):2597-2606. PubMed ID: 37704895
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the Effects of Renal Impairment on Clearance for Organic Cation Drugs that Undergo Renal Secretion: A Simulation-Based Study.
Follman KE; Morris ME
Drug Metab Dispos; 2018 May; 46(5):758-769. PubMed ID: 29490902
[TBL] [Abstract][Full Text] [Related]
10. Uremic Toxin Clearance and Cardiovascular Toxicities.
Mair RD; Sirich TL; Meyer TW
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29865226
[TBL] [Abstract][Full Text] [Related]
11. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.
Sandoval PJ; Zorn KM; Clark AM; Ekins S; Wright SH
Mol Pharmacol; 2018 Sep; 94(3):1057-1068. PubMed ID: 29884691
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.
Obianom ON; Coutinho AL; Yang W; Yang H; Xue F; Shu Y
Mol Pharm; 2017 Aug; 14(8):2726-2739. PubMed ID: 28699756
[TBL] [Abstract][Full Text] [Related]
14. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter.
Schophuizen CM; Wilmer MJ; Jansen J; Gustavsson L; Hilgendorf C; Hoenderop JG; van den Heuvel LP; Masereeuw R
Pflugers Arch; 2013 Dec; 465(12):1701-14. PubMed ID: 23812163
[TBL] [Abstract][Full Text] [Related]
15. The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance.
Kumar V; Yin J; Billington S; Prasad B; Brown CDA; Wang J; Unadkat JD
Drug Metab Dispos; 2018 Oct; 46(10):1441-1445. PubMed ID: 30093416
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Klamerus KJ; Alvey C; Li L; Feng B; Wang R; Kaplan I; Shi H; Dowty ME; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):499-507. PubMed ID: 27129125
[TBL] [Abstract][Full Text] [Related]
17. JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats.
Wen S; Wang C; Huo X; Meng Q; Liu Z; Yang S; Zhu Y; Sun H; Ma X; Liu K
Toxicol Lett; 2018 Oct; 295():195-204. PubMed ID: 29964132
[TBL] [Abstract][Full Text] [Related]
18. Interaction of beta-blockers with the renal uptake transporter OCT2.
Bachmakov I; Glaeser H; Endress B; Mörl F; König J; Fromm MF
Diabetes Obes Metab; 2009 Nov; 11(11):1080-3. PubMed ID: 19740083
[TBL] [Abstract][Full Text] [Related]
19. Impaired Tubular Secretion of Organic Solutes in Advanced Chronic Kidney Disease.
Mair RD; Lee S; Plummer NS; Sirich TL; Meyer TW
J Am Soc Nephrol; 2021 Nov; 32(11):2877-2884. PubMed ID: 34408065
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
